EU-101 is under clinical development by Eutilex and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect EU-101’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 27 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their EU-101 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

EU-101 overview

EU-101 is under development for the treatment of solid tumors including non-small cell lung cancer and colorectal cancer. The therapeutic candidate is a monoclonal antibody developed based on the immunomodulatory platform technology. It is administered by intravenous route and acts by targeting 4-1BB also called CD137.

Eutilex overview

Eutilex Co. Ltd., a clinical-stage biopharmaceutical company that develops immunotherapy technology, anti tumor T cell therapy and antibody therapeutics, and other technology products. The company is headquartered in Republic of Korea (South Korea).

Quick View EU-101 LOA Data

Report Segments
  • Innovator
Drug Name
  • EU-101
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.